Bills / H.R. 8205
H.R. 8205
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
In plain English
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This act reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The act reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases. Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs. Additionally, the FDA must publish a plan describing actions it will tak
Congressional Research Service summary from Congress.gov (not yet simplified).
Sponsor and status
Loading from Congress.gov…
How South Carolina voted
No recorded roll-call vote on this bill yet. Most bills never get one.
Who lobbied
Lobbying reports name the bills a client worked on. They don't say which side anyone took.
No lobbying reported on this bill in the reports we have loaded (January 2025 through September 2026). Lobbyists report each quarter, about 20 days after it ends, so any lobbying since October 2026 will be added once those reports are filed.